Concordia to Acquire Amdipharm Mercury for $3.5 Billion

Concordia Healthcare is acquiring UK-based Amdipharm Mercury for $3.5 billion, in a deal that greatly expands the Canadian drugmaker’s generic portfolio and global reach.

The acquisition gives Corcordia access to AMCo’s portfolio of more than 190 off-patent molecules for conditions ranging from glaucoma and epilepsy to high blood pressure, as well as new therapeutic areas in endocrinology, urology and ophthalmology. Ontario-based Concordia produces legacy pharmaceuticals and orphan drugs.

The deal also creates a global platform for Concordia via AMCo’s commercial presence in more than 100 countries.

The purchase, which is expected to close in the fourth quarter, includes the assumption of $1.4 billion in AMCo debt, as well as a maximum performance-based payout of about $220 million.

Concordia estimates that the combined company could make $870 million to $920 million in revenue for 2015. — Victoria Pelham